Health and Human Services Department, Food and Drug Administration
The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2026-N-0008] AGENCY: Food and Drug Administration, HHS. ACTION: Notice; termination and reestablishment of Federal advisory committee. SUMMARY: The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished. DATES: Authority for the Peripheral and Central Nervous System Drugs Advisory Committee will reestablish on July 30, 2026. FOR FURTHER INFORMATION CONTACT: Advisory Committee Oversight and Management Staff, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993-0002, (301) 796-8220, ACOMSSubmissions@fda.hhs.gov . SUPPLEMENTARY INFORMATION: Pursuant to 21 CFR 14.55(b) ; 21 CFR 14.40(b) and 41 CFR 102-3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the termination and reestablishment of the Peripheral and Central Nervous System Dru…
Other Federal Register documents from the same docket.
Advisory Committee; Science Board to the Food and Drug Administration; Renewal
Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal
Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
Advisory Committee; Blood Products Advisory Committee; Renewal
Citation: 91 FR 46444
